Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CB 101 - Cantabio Pharmaceuticals

Drug Profile

CB 101 - Cantabio Pharmaceuticals

Alternative Names: CB-101 - Cantabio Pharmaceuticals

Latest Information Update: 15 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gardedam Therapeutics; Purdue University
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Protein deglycase DJ-1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 06 Sep 2023 CB 101 - Cantabio Pharmaceuticals is available for licensing as of 06 Sep 2023. https://www.cantabio.com/scientific-approach/pipeline.html
  • 31 Aug 2023 Preclinical trials in Parkinson's disease in USA (unspecified route) (before August 2023) (Cantabio Pharmaceuticals Pipeline, August 2023)
  • 11 Jul 2016 Cantabio Pharmaceuticals signs a cooperation agreement with Purdue Research Foundation for studies on pharmacological chaperones for Parkinson's disease and other neurodegenerative disorders
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top